The estimated Net Worth of Dwight E Ellingwood is at least $379 Thousand dollars as of 4 October 2018. Mr. Ellingwood owns over 1,000 units of Meridian Bioscience stock worth over $271,760 and over the last 10 years he sold VIVO stock worth over $0. In addition, he makes $107,000 as Independent Director at Meridian Bioscience.
Dwight has made over 6 trades of the Meridian Bioscience stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 1,000 units of VIVO stock worth $12,800 on 4 October 2018.
The largest trade he's ever made was exercising 3,000 units of Meridian Bioscience stock on 13 June 2016 worth over $52,020. On average, Dwight trades about 504 units every 83 days since 2014. As of 4 October 2018 he still owns at least 8,000 units of Meridian Bioscience stock.
You can see the complete history of Mr. Ellingwood stock trades at the bottom of the page.
Dwight E. Ellingwood serves as Independent Director of the Company. Dwight E. Ellingwood serves as Chairman of the Nominating and Corporate Governance Committee. With over 35 years of experience in health care strategy, planning, and business development, he currently is a teaching professor and associate director for practitioner experience in the Graduate Program of the Department of Health Services Administration at Xavier University in Cincinnati, Ohio. He founded D.E.E. Strategy Consulting, LLC, to advise health care clients. Mr. Ellingwood previously served as Senior Vice President of Strategy, Communications and Public Affairs for TriHealth in Cincinnati, Ohio (November 2014 – July 2016) and as the Lead Executive for the Collective Impact on Health, The Health Collaborative (January 2014 – November 2014). From 1997 through 2013, Mr. Ellingwood served as Senior Vice President, Planning and Business Development for Cincinnati Children’s Hospital Medical Center. The Board believes that the Company benefits greatly from Mr. Ellingwood’s extensive experience in strategy and business development in the health care industry.
As the Independent Director of Meridian Bioscience, the total compensation of Dwight Ellingwood at Meridian Bioscience is $107,000. There are 8 executives at Meridian Bioscience getting paid more, with John P. Kenny having the highest compensation of $1,508,705.
Dwight Ellingwood is 67, he's been the Independent Director of Meridian Bioscience since 2014. There are 3 older and 10 younger executives at Meridian Bioscience. The oldest executive at Meridian Bioscience Inc. is David Phillips, 81, who is the Independent Chairman of the Board.
Dwight's mailing address filed with the SEC is 3471 RIVER HILLS DRIVE, , CINCINNATI, OH, 45244.
Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny, and John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian Bioscience executives and other stock owners filed with the SEC include: